Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mario B. Guglielmi is active.

Publication


Featured researches published by Mario B. Guglielmi.


Journal of Medicinal Chemistry | 2008

Synthesis and Biological Activity of Fluorinated Combretastatin Analogues

Domenico Alloatti; Giuseppe Giannini; Walter Cabri; Isabella Lustrati; Mauro Marzi; Andrea Ciacci; Grazia Gallo; M. Ornella Tinti; Marcella Marcellini; Teresa Riccioni; Mario B. Guglielmi; Paolo Carminati; Claudio Pisano

With the aim of understanding the influence of fluorine on the double bond of the cis-stilbene moiety of combretastatin derivatives and encouraged by a preliminary molecular modeling study showing a different biological environment on the interaction site with tubulin, we prepared, through various synthetic approaches, a small library of compounds in which one or both of the olefinic hydrogens were replaced with fluorine. X-ray analysis on the difluoro-CA-4 analogue demonstrated that the spatial arrangement of the molecule was not modified, compared to its nonfluorinated counterpart. SAR analysis confirmed the importance of the cis-stereochemistry of the stilbene scaffold. Nevertheless, some unpredicted results were observed on a few trans-fluorinated derivatives. The position of a fluorine atom on the double bond may affect the inhibition of tubulin polymerization and cytotoxic activity of these compounds.


Journal of Medicinal Chemistry | 2014

Synthesis and Evaluation of New Hsp90 Inhibitors Based on a 1,4,5-Trisubstituted 1,2,3-Triazole Scaffold

Maurizio Taddei; Serena Ferrini; Luca Giannotti; Massimo Corsi; Fabrizio Manetti; Giuseppe Giannini; Loredana Vesci; Ferdinando Maria Milazzo; Domenico Alloatti; Mario B. Guglielmi; Massimo Castorina; Maria Luisa Cervoni; Marcella Barbarino; Rosanna Foderà; Valeria Carollo; Claudio Pisano; Silvia Armaroli; Walter Cabri

Ruthenium catalyzed 1,3-cycloaddition (click chemistry) of an azido moiety installed on dihydroxycumene scaffold with differently substituted aryl propiolates gave a new family of 1,4,5-trisubstituted triazole carboxylic acid derivatives that showed high affinity toward Hsp90 associated with cell proliferation inhibition, both in nanomolar range. The 1,5 arrangement of the resorcinol, the aryl moieties, and the presence of an alkyl (secondary) amide in position 4 of the triazole ring were essential to get high activity. Docking simulations suggested that the triazoles penetrate the Hsp90 ATP binding site. Some 1,4,5-trisubstituted triazole carboxamides induced dramatic depletion of the examined client proteins and a very strong increase in the expression levels of the chaperone Hsp70. In vitro metabolic stability and in vivo preliminary studies on selected compounds have shown promising results comparable to the potent Hsp90 inhibitor NVP-AUY922. One of them, (compound 18, SST0287CL1) was selected for further investigation as the most promising drug candidate.


Molecular Cancer Therapeutics | 2008

Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968

Claudio Pisano; Michelandrea De Cesare; Giovanni Luca Beretta; Valentina Zuco; Graziella Pratesi; Sergio Penco; Loredana Vesci; Rosanna Foderà; Fabiana Fosca Ferrara; Mario B. Guglielmi; Paolo Carminati; Sabrina Dallavalle; Lucio Merlini; Augusto Orlandi; Franco Zunino

ST1968 is a novel hydrophilic camptothecin (CPT) derivative of the 7-oxyiminomethyl series. Because ST1968 retained ability to form remarkably stable cleavable complexes, this study was done to investigate its preclinical profile of antitumor activity in a large panel of human tumor models, including irinotecan-resistant tumors. Although less potent than SN38 in vitro, i.v. administered ST1968 caused a marked tumor inhibition, superior to that of irinotecan, in most tested models. ST1968 exhibited an impressive activity against several tumors including models of ovarian and colon carcinoma in which a high rate of cures was observed. In the most responsive tumors, complete and persistent tumor regressions were achieved even with low suboptimal doses. Even tumors derived from intrinsically resistant cells exhibited a significant responsiveness. Histologic analysis of treated tumors supports a contribution of both proapoptotic and antiangiogenic effects to ST1968 antitumor efficacy. A study done in yeast cells transformed with CPT-resistant mutant forms of topoisomerase I documented that, in contrast to other tested CPT, ST1968 was active against yeasts expressing the mutant K720E enzyme. Based on its outstanding efficacy superior to that of irinotecan and of its good therapeutic index, ST1968 has been selected for clinical development. [Mol Cancer Ther 2008;7(7):2051–9]


Journal of Medicinal Chemistry | 2011

Novel 3,4-isoxazolediamides as potent inhibitors of chaperone heat shock protein 90.

Riccardo Baruchello; Daniele Simoni; Giuseppina Grisolia; Giuseppina Barbato; Paolo Marchetti; Riccardo Rondanin; Stefania Mangiola; Giuseppe Giannini; Tiziana Brunetti; Domenico Alloatti; Grazia Gallo; Andrea Ciacci; Loredana Vesci; Massimo Castorina; Ferdinando Maria Milazzo; Maria Luisa Cervoni; Mario B. Guglielmi; Marcella Barbarino; Rosanna Foderà; Claudio Pisano; Walter Cabri

A structural investigation on the isoxazole scaffold led to the discovery of 3,4-isoxazolediamide compounds endowed with potent Hsp90 inhibitory properties. We have found that compounds possessing a nitrogen atom directly attached to the C-4 heterocycle ring possess in vitro Hsp90 inhibitory properties at least comparable to those of the structurally related 4,5-diarylisoxazole derivatives. A group of compounds from this series of diamides combine potent binding affinity and cell growth inhibitory activity in both series of alkyl- and aryl- or heteroarylamides, with IC50 in the low nanomolar range. The 3,4-isoxazolediamides were also very effective in causing dramatic depletion of the examined client proteins and, as expected for the Hsp90 inhibitors, always induced a very strong increase in the expression levels of the chaperone Hsp70. In vivo studies against human epidermoid carcinoma A431 showed an antitumor effect of morpholine derivative 73 comparable to that induced by the reference compound 10.


Clinical Cancer Research | 2010

Metabolic Approach to the Enhancement of Antitumor Effect of Chemotherapy: A Key Role of Acetyl-L-Carnitine

Claudio Pisano; Loredana Vesci; Ferdinando Maria Milazzo; Mario B. Guglielmi; Rosanna Foderà; Marcella Barbarino; Maurizio D'Incalci; Massimo Zucchetti; Giovanna Petrangolini; Monica Tortoreto; Paola Perego; Valentina Zuco; Augusto Orlandi; Daniela Passeri; Paolo Carminati; Claudio Cavazza; Franco Zunino

Purpose: Acetyl-l-carnitine (ALC) plays a relevant role in energy metabolism and stress response because of its function in the complex metabolic system regulating the acetyl-CoA levels that provide a source of acetyl groups for metabolic and acetylation-regulated processes. Because acetylation may influence p53 activity/stability and, therefore, the response to platinum compounds, this study was designed to investigate the effect of ALC in combination with platinum compounds. Experimental Design: The antiproliferative and antitumor activity studies were done in a panel of human tumor cell lines with functional or defective p53. The antimetastatic drug efficacy was investigated in the s.c. growing H460/M tumor subline, which is able to generate lung metastases. Results: ALC enhanced the sensitivity to cisplatin of tumor cells with functional p53. The sensitization by ALC was reflected in an improved in vivo antitumor efficacy of the combination over cisplatin alone in wild-type p53 lung tumors. ALC did not increase the cisplatin efficacy in the p53-mutant SW620 tumor. ALC exhibited a significant antimetastatic activity, and this effect was better exploited in combination with the histone deacetylase inhibitor, ST3595. The in vivo ALC/cisplatin combination caused the activation of p53, associated with protein acetylation and induction of target genes. Conclusions: ALC was effective in enhancing the antitumor potential of platinum compounds in wild-type p53 tumors. ALC, alone and in combination with a histone deacetylase inhibitor, exhibited an outstanding antimetastatic activity. Both effects, likely mediated by protein acetylation, may have implications for platinum-based therapy and combinations with histone deacetylase inhibitors. Clin Cancer Res; 16(15); 3944–53. ©2010 AACR.


Journal of Medicinal Chemistry | 2014

ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors.

Giuseppe Giannini; Loredana Vesci; Gianfranco Battistuzzi; Davide Vignola; Ferdinando Maria Milazzo; Mario B. Guglielmi; Marcella Barbarino; Mose ̀ Santaniello; Nicola Fanto; Marco Mor; Silvia Rivara; Daniele Pala; Maurizio Taddei; Claudio Pisano; Walter Cabri

A systematic study of medicinal chemistry aimed at identifying a new generation of HDAC inhibitors, through the introduction of a thiol zinc-binding group (ZBG) and of an amide-lactam in the ω-position of the polyethylene chain of the vorinostat scaffold, allowed the selection of a new class of potent pan-HDAC inhibitors (pan-HDACis). Simple, highly versatile, and efficient synthetic approaches were used to synthesize a library of these new derivatives, which were then submitted to a screening for HDAC inhibition as well as to a preliminary in vitro assessment of their antiproliferative activity. Molecular docking into HDAC crystal structures suggested a binding mode for these thiol derivatives consistent with the stereoselectivity observed upon insertion of amide-lactam substituents in the ω-position. ST7612AA1 (117), selected as a drug candidate for further development, showed an in vitro activity in the nanomolar range associated with a remarkable in vivo antitumor activity, highly competitive with the most potent HDAC inhibitors, currently under clinical trials. A preliminary study of PK and metabolism is also illustrated.


Bioorganic & Medicinal Chemistry Letters | 2014

Novel PARP-1 inhibitors based on a 2-propanoyl-3H-quinazolin-4-one scaffold.

Giuseppe Giannini; Gianfranco Battistuzzi; Loredana Vesci; Ferdinando Maria Milazzo; Francesca De Paolis; Marcella Barbarino; Mario B. Guglielmi; Valeria Carollo; Grazia Gallo; Roberto Artali; Sabrina Dallavalle

Poly(ADP-ribose)polymerase-I (PARP-1) enzyme is involved in maintaining DNA integrity and programmed cell death. A virtual screening of commercial libraries led to the identification of five novel scaffolds with inhibitory profile in the low nanomolar range. A hit-to-lead optimization led to the identification of a group of new potent PARP-1 inhibitors, acyl-piperazinylamides of 3-(4-oxo-3,4-dihydro-quinazolin-2-yl)-propionic acid. Molecular modeling studies highlighted the preponderant role of the propanoyl side chain.


Bioorganic & Medicinal Chemistry | 2012

New retinoid derivatives as back-ups of Adarotene

Giuseppe Giannini; Tiziana Brunetti; Gianfranco Battistuzzi; Domenico Alloatti; Gianandrea Quattrociocchi; Maria Grazia Cima; Lucio Merlini; Sabrina Dallavalle; Raffaella Cincinelli; Raffaella Nannei; Loredana Vesci; Federica Bucci; Rosanna Foderà; Mario B. Guglielmi; Claudio Pisano; Walter Cabri

Adarotene belongs to the so-called class of atypical retinoids. The presence of the phenolic hydroxyl group on Adarotene structure allows a rapid O-glucuronidation as a major mechanism of elimination of the drug, favoring a fast excretion of its glucuronide metabolite in the urines. A series of ether, carbamate and ester derivatives was synthesized. All of them were studied and evaluated for their stability at different pH. The cytotoxic activity in vitro on NCI-H460 non-small cell lung carcinoma and A2780 ovarian tumor cell lines was also tested. A potential back-up of Adarotene has been selected to be evaluated in tumor models.


PLOS ONE | 2018

Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents

Raffaella Cincinelli; Loana Musso; Roberto Artali; Mario B. Guglielmi; Ilaria La Porta; Carmela Melito; Fabiana Colelli; Francesco Cardile; Giacomo Signorino; Alessandra Fucci; Martina Frusciante; Claudio Pisano; Sabrina Dallavalle

Recent studies have shown that HDAC inhibitors act synergistically with camptothecin derivatives in combination therapies. To exploit this synergy, new hybrid molecules targeting simultaneously topoisomerase I and HDAC were designed. In particular, a selected multivalent agent containing a camptothecin and a SAHA-like template showed a broad spectrum of antiproliferative activity, with IC50 values in the nanomolar range. Preliminary in vivo results indicated a strong antitumor activity on human mesothelioma primary cell line MM473 orthotopically xenografted in CD-1 nude mice and very high tolerability.


Journal of Medicinal Chemistry | 2018

Alkyl-guanidine compounds as potent broad-spectrum antibacterial agents: chemical library extension and biological characterization.

Carolina Pasero; Ilaria D'agostino; Filomena De Luca; Claudio Zamperini; Davide Deodato; Giuseppina Ivana Truglio; Filomena Sannio; Rosita Del Prete; Teresa Ferraro; Daniela Visaggio; Arianna Mancini; Mario B. Guglielmi; Paolo Visca; Jean-Denis Docquier; Maurizio Botta

Nowadays, the increasing of multidrug-resistant pathogenic bacteria represents a serious threat to public health, and the lack of new antibiotics is becoming a global emergency. Therefore, research in antibacterial fields is urgently needed to expand the currently available arsenal of drugs. We have recently reported an alkyl-guanidine derivative (2), characterized by a symmetrical dimeric structure, as a good candidate for further developments, with a high antibacterial activity against both Gram-positive and Gram-negative strains. In this study, starting from its chemical scaffold, we synthesized a small library of analogues. Moreover, biological and in vitro pharmacokinetic characterizations were conducted on some selected derivatives, revealing notable properties: broad-spectrum profile, activity against resistant clinical isolates, and appreciable aqueous solubility. Interestingly, 2 seems neither to select for resistant strains nor to macroscopically alter the membranes, but further studies are required to determine the mode of action.

Collaboration


Dive into the Mario B. Guglielmi's collaboration.

Researchain Logo
Decentralizing Knowledge